Literature DB >> 1622443

General pharmacology of the new quinolone antibacterial agent levofloxacin.

K Takasuna1, Y Kasai, C Usui, M Takahashi, M Hirohashi, K Tamura, S Takayama.   

Abstract

The general pharmacological properties of (-)-(S)-9-fluoro-2,3-dihydro-3- methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4] benzoxazine-6-carboxylic acid hemihydrate (levofloxacin, DR-3355, CAS 100986-85-4), an optically active isomer of ofloxacin, were examined. 1. Central nervous system (CNS): DR-3355 at 200-600 mg/kg p.o. showed depressant activity on the CNS, as was indicated by the depressant syndrome (mice), decreased spontaneous motor activity (mice) and hypothermia (mice and rabbits). In the cat behavior and EEG experiments, it had both stimulant and depressant effects at 30-100 mg/kg i.p., and caused transient slow waves followed by seizures at 20-30 mg/kg i.v. DR-3355 had no effect on convulsion, hexobarbital anesthesia, pain reaction to a tail pinch, or conditioned avoidance response, except that it showed mild analgesic activity in acetic acid writhing at 600 mg/kg p.o. 2. Respiratory and cardiovascular system: DR-3355 produced a hypotensive and a bradycardiac effect after the rapid i.v. injection of 6 mg/kg or more in anesthetized dogs, accompanied by an increase in plasma histamine concentration. Both changes were markedly reduced when the test drug was administered by continuous i.v. infusion. 3. Autonomic nervous system: DR-3355 inhibited nictitating membrane contraction induced by both pre- and post-ganglionic stimulation, and inhibited the depressor response to acetylcholine at 20 mg/kg i.v. It had no influence on pupil size or on pressor response to norepinephrine. 4. Gastrointestinal system: DR-3355 at 600 mg/kg p.o. inhibited gastric secretion. Dog gastrointestinal motility was slightly inhibited, and was then stimulated over the dose range of 2-20 mg/kg i.v. It had no influence on gastrointestinal propulsion, the gastric emptying rate or the gastric mucosa. 5. Isolated smooth muscle: At a concentration of 5 x 10(-4) g/ml, DR-3355 was devoid of spasmogenic or smasmolytic activity, except for showing a slight relaxation effect (trachea), inhibition of nicotine-induced contraction (ileum) and spontaneous or oxytocin-induced motility (pregnant uterus). 6. Miscellaneous: DR-3355 inhibited the urine output and carrageenin-induced paw edema at 600 mg/kg p.o. It had no effect on skeletal muscle contraction or the corneal reflex.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622443

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  5 in total

1.  Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.

Authors:  A L Baltch; R P Smith; W Ritz
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

2.  Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila.

Authors:  A L Baltch; R P Smith; M A Franke; P B Michelsen
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

3.  Flush induced by fluoroquinolones in canine skin.

Authors:  M Kurata; Y Kasuga; E Nanba; H Nakamura; T Asano; K Haruta
Journal:  Inflamm Res       Date:  1995-11       Impact factor: 4.575

4.  Determination of key residues in MRGPRX2 to enhance pseudo-allergic reactions induced by fluoroquinolones.

Authors:  Eri Hamamura-Yasuno; Junya Matsushita; Seiji Sato; Takashi Shimada; Yoshimi Tsuchiya; Kazunori Fujimoto; Kazuhiko Mori
Journal:  Sci Rep       Date:  2022-04-22       Impact factor: 4.996

5.  Identification of the dog orthologue of human MAS-related G protein coupled receptor X2 (MRGPRX2) essential for drug-induced pseudo-allergic reactions.

Authors:  Eri Hamamura-Yasuno; Takuma Iguchi; Kazuyoshi Kumagai; Yoshimi Tsuchiya; Kazuhiko Mori
Journal:  Sci Rep       Date:  2020-09-30       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.